Efficient identification of candidates for clinical success
Successful translation of a therapeutic antibody candidate to the clinic depends on its physicochemical properties. Antibody degradation or instability for example, can have a great impact on its biological function. IPA streamlines in silico and in vitro processes with high-throughput workflows for developability profiling, by assessing critical antibody quality attributes.
IPA’s workflow is based on throughput and parallel efforts to monitor potential liabilities in an early stage. Based on the developability assessment, lead antibodies can be subjected to sequence optimization to enhance success rate for clinical translation.
In Silico Analysis
IPA’s in silico developability profiling toolset includes sequence analysis, Fv model-based structure analysis, and Fv model-based surface analysis for antibody lead candidates to identify e.g. chemical liability motifs, aggregation prone regions, and charge properties. These in silico engineering approaches facilitate focused antibody de-risking, if required, to improve the mAb developability profile.
In Vitro Analysis
In vitro analytical tools allow for the study of various critical quality attributes like production yield, target- and/or poly-reactivity, colloidal stability, melting temperature, self- and/or cross-interaction, solubility, and fragmentation.
IPA is equipped with a state-of-the-art bio-inert HPLC enabling analytical determination of mAb biochemical and biophysical properties such as aggregation levels (SEC-HPLC), colloidal stability (SMAC-HPLC), cross interaction (CIC-HPLC), Asn deamidation and isomerization (CIEX-HPLC), and Met/Trp oxidation (HIC-HPLC).
1. ROOTS 2022: Antibody Discovery Services and Platforms Market (4th Edition), 2021-2035; p.118
Lead the way with IPA.
We have the longest memory
Rabbit monoclonal antibodies with B Cell Select® with Function-First from IPA are unmatched for early identification of a high affinity, highly specific antibodies.
Bi specifics & IPA
Bring us your scaffold and we can do the rest. With years of experience using a variety of bi- and multi-specific modalities, IPA has end-to-end capabilities and throughput to ensure selection and development of the most relevant therapeutic candidates.
Wet lab + in silico
LENSai in silico applications for radically informed decisions are designed to lend great cost and time efficiencies, as part of the IPA antibody discovery portfolio of service.
Additional antibody discovery products